Kornimate/medical-research-clean huggingface dataset:
the causative insects in severe insect sting allergy

Conditions: Insect Sting Allergy

Summary: study the causative insect by skin prick test and sige to wasp, bee and fire ants are important but false positive by crossreactivity can occur. sige to recombinant venom allergen is proposed to help in finding the causative insect.

insect sting allergy from insects in hymenoptera is not uncommon. the reaction maybe very severe and life threatening. to find the cause of insect sting allergy is important in prevention and specific treatment such as immunotherapy. the skin prick test and sige of these insects may have cross reactions so it is difficult to be interpreted. the usage of sige recombinant venom allergen can benefit in separate cross reaction and dual allergy reaction.

Eligibility criteria:
inclusion criteria: * cases with severe insect sting allergy reactions exclusion criteria: * without other severe systemic diseases * not pregnant or lactation

Keywords: insect sting allergy recombinant venom allergen
the efficacy of different vitamin d supplementation delivery methods

Conditions: Vitamin D Deficiency

Summary: to test the efficacy of different vitamin d delivery methods on serum 25(oh)d. participants randomly assigned to one of seven groups - three placebo groups and 4 active supplement groups receiving 100,000iu vitamin d3

various delivery methods of vitamin d supplementation are available to consumers but there have been no studies providing evidence of whether one delivery method is superior to others. the researchers wanted to compare the delivery of 100,000iu vitamin d3 by three methods on serum 25(oh)d levels. two methods of oral supplementation (pill \[prolonged release\] and liquid \[immediate release\]), and delivery through the skin (with and without a penetrator enhancer. placebo groups were pill, oral liquid and skin applied oil

Eligibility criteria:
inclusion criteria: * healthy, female exclusion criteria: * any participant that was taking vitamin supplementation, had a skin condition that would prevent them from applying oil to their skin or were taking, or had been taking in the past 6-months, oestrogen based contraception
randomized evaluation for failed tavr

Conditions: Symptomatic Patients Who Have Had Transcatheter Heart Valve (THV) Failure; Prosthetic Valve Malfunction; Prosthesis Failure

Summary: revive tavr is an acronym for the randomized evaluation of valve-in-valve versus explantation for failed tavr. this is a prospective, multicenter, global randomized trial investigating the safety and efficacy of reintervention for transcatheter heart valve (thv) failure by comparing redo-tavr (tav-in-tav) with tavr surgical explantation (tavr-explant) in subjects who are suitable for both options in a real-world clinical setting


Eligibility criteria:
inclusion criteria: * heart team has confirmed eligibility for both tavr-explant and redo-tavr for failed thv * subject is symptomatic from their failed thv, as demonstrated by nyha functional class ≥ii * subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits * subject meets the legal minimum age to provide informed consent based on local regulatory requirements. exclusion criteria: * ongoing sepsis, including active endocarditis; * severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits); * other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams; * pregnancy or intent to become pregnant for the next 12 months; coronary obstruction risk: - patients at risk of coronary obstruction may be enrolled into the randomized cohort if the operators determine that redo-tavr can be safely accomplished with leaflet modification or other coronary protection strategies.
probing neural circuitry for the control of movement

Conditions: Neurological Movement Disorders

Summary: the investigators are interested in examining 1) the basic organization of spinal and cortical circuitry for the control of movement and 2) the influence of injury of these circuits. to investigate the neuronal circuitry, the investigators use various types of mechanical or electrical stimulation of the limbs, transcranial magnetic stimulation of the cortex and galvanic vestibular stimulation in both uninjured human subjects and subjects with a neurological injury (such as spinal cord injury, or parkinsons's disease).


Eligibility criteria:
inclusion criteria: * control subjects: no neurological movement disorder * patients: neurological movement disorder exclusion criteria: patients and control subjects: * presence of any central psychiatric disorder that precludes subject from giving informed and voluntary consent * presence of any cardiovascular conditions or limitations that restrict the ability to walk on a treadmill continuously for more than 20 minutes * for the electrical stimulation examination, subjects with metal implants are also excluded * for the tms and gvs examination, subjects with the following conditions are excluded: metal implants in the head, cardiac pacemakers, history of migraine headaches, history of major head injury, history of stroke, history of seizures, previous brain neurosurgery, unstable medical conditions, major psychiatric disorders, pregnancy -
a phase iii extended clinical trial of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: to observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis

if the enrolled subjects received the treatment of jaktinib hydrochloride tablets in the zgjak025 trial, they will continue to use the drug at the original dosage; if the enrolled subjects received placebo treatment in the zgjak025 trial, they will receive 100mg bid of jaktinib hydrochloride tablets, 75mg bid of jaktinib hydrochloride tablets or placebo at a ratio of 1:1:1 at random, and continue to take the drug on an empty stomach, with the longest continuous treatment not exceeding 36 weeks.

Eligibility criteria:
inclusion criteria: * the investigator thinks that the subject can continue to benefit from participating in the extension trial; * fully understand the extension trial and sign the informed consent form; * complete the zgjak025 trial for 16 weeks and have good compliance; * it is expected that the time interval between the first administration and the last administration of zgjak025 trial for the subject should be ≤ 4 weeks; exclusion criteria: * within 4 weeks before enrollment, there were any adverse events ≥ 3 levels related to the test drug that did not return to level 1 or normal; * the investigator thinks that the subject is not suitable for the trial.
submassive pulmonary embolism experience with ekos

Conditions: Thrombolytic Therapy; Thrombolysis; Mechanical Thrombolysis; Pulmonary Embolism

Summary: this single site study evaluates the efficacy of ultrasound accelerated thrombolysis using ekos endovascular device with a standard infusion of thrombolytics for treatment of pe

previous clinical trials examining thrombolytics used to treat acute submassive pe, many times will use fixed dose and duration. little research has been conducted on the physiologic implication of resolution of symptoms. it seems reasonable, that symptomatic relief results from some degree of hemodynamic normalization. this study will seek to examine the extent to which the hemodynamic impairment is normalized from a thrombolytic treatment protocol with an endpoint of therapy determined as resolution of presenting symptoms. treatment plans will utilize the mbs (modified borg scale) score to help evaluate and measure outcome-based care, quantifying shortness of breath.

Eligibility criteria:
inclusion criteria: 1. acute symptomatic pe confirmed by ct, with filling defect in at least one main or segmental pulmonary artery. 2. rv dysfunction as evidenced by rv/lv ratio \> 0.9 on echo 3. ability to give informed consent or legally authorized representative (lar) is able to give consent 4. pe symptom duration \< 21 days 5. age \>18 years 6. and, a mbs baseline measurement above 3 plus at least one of the following: o2 sat \ 100. whichever measurement is chosen for inclusion criteria in addition to the mbs will also be used in determination of therapeutic endpoint (i.e. o2 sat., hr\ 100).. exclusion criteria: 1. stroke or transient ischemic attack (tia), head trauma, or other active intracranial or intraspinal disease within one year 2. recent (within one month) or active bleeding from a major organ 3. hemoglobin (hgb) \< 8.0 4. platelets \< 60 thousand/µl 5. major surgery within seven days 6. clinician deems high-risk for catastrophic bleeding 7. history of heparin-induced thrombocytopenia (hit) 8. pregnancy 9. catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment 10. systolic blood pressure less than 80 mm hg despite vasopressor or inotropic support 11. cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (cpr) 12. evidence of irreversible neurological compromise 13. life expectancy \< 30 days 14. use of thrombolytics or glycoprotein iib/iiia antagonists within 3 days prior to inclusion in the study

Keywords: thrombolysis ultrasound thrombolysis pulmonary embolism saddle pe submassive pe massive pe bilateral pe
native-changing high-risk alcohol use and increasing contraception effectiveness study

Conditions: Contraceptive Usage; Alcohol Use Complicating Childbirth; Alcohol Drinking

Summary: native choices is a randomized controlled trial of an adapted intervention to reduce the risk of alcohol exposed pregnancies in american indians and alaska natives (ai/ans). we will enroll 350 ai/an women living on the cheyenne river sioux indian reservation or in rapid city in south dakota who are 18-44 years old, have risky drinking behaviors, are not currently pregnant but are able to become pregnant, and are sexually active but not using effective contraception.

fetal alcohol spectrum disorder (fasd) prevalence is up to 10 times higher in american indians and alaska natives (ai/ans) than in the general us population, yet fasd is 100% preventable. even moderate alcohol use during pregnancy can affect fetal growth and behavioral outcomes. alcohol use disorders and binge drinking in women are among the strongest risk factors for fasd in their offspring. ai/ans have the highest prevalence of alcohol use disorders among us racial and ethnic groups, and are the most likely to engage in binge drinking during pregnancy. a growing consensus indicates that prevention of alcohol-exposed pregnancy must begin before conception. one promising approach is the changing high-risk alcohol use and increasing contraception effectiveness study (choices), which combines motivational interviewing with contraception counseling for non-pregnant women. in a randomized trial, women receiving choices were 36% more likely to have reduced risk for alcohol-exposed pregnancies after 6 months than women receiving usual care, but the trial did not enroll ai/ans or rural women. although the centers for disease control and prevention has recommended its dissemination, the public health value and cost-effectiveness of choices in ai/ans is unknown. we propose a randomized controlled trial of an adapted intervention - native-choices - to reduce risk of alcohol exposed pregnancies in ai/ans. we will enroll 350 ai/an women living on the cheyenne river sioux indian reservation or in rapid city in south dakota who are 18-44 years old, have risky drinking behaviors, are not currently pregnant but are able to become pregnant, and are sexually active but not using effective contraception. native-choices will consist of 2 motivational interviewing sessions plus 1 contraceptive counseling session over 4 weeks, with supportive electronic messaging for 3 months to increase perceived social connectedness and support for modifying drinking behavior and using contraception.

Eligibility criteria:
inclusion criteria: * native american woman * 18-44 years old at the time of recruitment * self-report high-risk drinking behavior (average 8 or more drinks per week) or episodes of binge drinking (four or more drinks on a single occasion) in the past 90 days * have vaginal sex with a male partner in the past 30 days exclusion criteria: * diagnosed as infertile * pregnant * effectively using contraceptives defined by standard methods * living in a household with someone who is already enrolled in the study
a prospective, multicenter, open-label study of the beacon platform for holmium laser enucleation of the prostate (holep)

Conditions: Benign Prostatic Hyperplasia

Summary: robotic assisted surgery for benign prostatic hyperplasia (bph)

a single-arm open label pilot study observing intraoperative and postoperative outcomes of the beacon platform in holep.

Eligibility criteria:
inclusion criteria: 1. male 2. subject has diagnosis of lower urinary tract symptoms and/or urinary retention due to benign prostatic enlargement causing bladder outlet obstruction, 3. subject is able and willing to comply with all the assessments of the study, 4. subject or subject's legal representative has been informed of the nature of the study, agrees to participate, and has signed the informed consent form, 5. ≥ 45 years of age, 6. prostate volume 40 - 120 cc by transrectal ultrasound (trus), magnetic resonance imaging (mri), or computed tomography (ct), measured within one year prior to procedure, 7. the subject is indicated for undergoing holep procedure exclusion criteria: 1. urethral stricture, meatal stenosis, or bladder neck contracture - either current or recurrent, 2. history of prostate cancer or current/suspected bladder cancer, 3. prostate cancer should be ruled out before participation to the satisfaction of the investigator if prostate-specific antigen (psa) is above acceptable thresholds, 4. history of other diseases causing voiding dysfunction including urinary retention (e.g., diagnosis of neurogenic bladder, parkinson's disease, multiple sclerosis, etc.), 5. subjects with overactive bladder in the absence of benign prostatic obstruction as determined by the investigator, 6. acute urinary tract infection (uti) or finding of asymptomatic bacteriuria (note: subject can be enrolled if the uti is treated) 7. previous pelvic irradiation or radical pelvic surgery, 8. previous prostate surgery, including enucleation, resection, vaporization, thermotherapy, ablation, stenting, or prostatic urethral lift, 9. inability to stop taking anticoagulants for at least 3 days prior to the procedure or antiplatelets and/or coumadin for at least 5 days prior to the procedure (note: low dose aspirin therapy is permitted), 10. any severe illness that would prevent complete study participation or confound study results. 11. bleeding tendency disorders, 12. future fertility concerns, 13. subject has any other disease or condition(s) that would interfere with completion of the study and follow-up assessments, would increase risks of the procedure, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect outcomes, 14. concomitant participation in another interventional study

Keywords: holep rolep robotic holep bph prostate urology robotic andromeda astra
serum preptin level and its relationship with bone mineral disease in chronic kidney disease patients

Conditions: Preptin

Summary: aim of the research:to identify preptin level and relationship with bone disease in chronic kidney disease patients.

preptin is a 34-aminoacid peptide derived from the e-peptide of pro-insulin-like growth factor 2 (pro-igf2) that is co-secreted with insulin and upregulates glucose-mediated insulin secretion. high serum preptin levels were described in conditions associated with insulin resistance, such as polycystic ovary syndrome and type 2 diabetes mellitus (t2m). insulin and also igf2 are known to be anabolic bone hormones . preptin stimulates osteoblastic proliferation and increases mineralization in a concentration-independent manner in osteoblast precursor cell , despite being associated with insulin resistance, an increased fat mass has beneficial bone effects . while the increased mechanical loading favors bone formation, adipokines and also pancreatic and gut hormones were also proposed to mediate the relationship between fat and bone. the importance of nutritional hormones in maintaining bone mass was, thus, recognized. insulin has anabolic bone effects, and hyperinsulinemia contributes to increased bone mineral density (bmd). similar to insulin, insulin-like growth factor 1 (igf1) and igf2, preptin was recently proposed to have anabolic bone activity . end-stage renal disease (esrd) patients present with specific bone and mineral metabolism disturbances. chronic kidney disease-associated mineral and bone disorder accounts for increased morbidity and mortality in those patients. biochemical markers known thus far do not effectively predict the complex bone changes that are observed in esrd patients .

Eligibility criteria:
inclusion criteria: * both sex groups of patients with age between 18-50 years . pre end stage renal disease and end stage renal disease patients . exclusion criteria: * type 2 diabetic patients

Keywords: chronic kidney preptin
wearable technologies for sleep in children and adolescents

Conditions: Sleep; Pediatric Sleep Apnea

Summary: this study aims to evaluate the viability of wearable and portable technologies for sleep staging in children and adolescents. the results will be compared with polysomnography, in order to achieve clinical and diagnostic validation. three domains of devices will be used: movement sensors, wearable eeg band and pulse oximetry. the project will include individuals between the ages of 3 and 18 who reside in são paulo city and undergo a polysomnography test at the sleep laboratory of the children's institute of the hospital das clínicas of the university of são paulo, achieving a minimum of 85% sleep efficiency on the night of the test.

this study aims to evaluate the viability of the combined use of wearable and portable technologies for sleep staging. the results will be compared with polysomnography, in order to achieve clinical and diagnostic validation. three domains of devices will be used: * movement sensors: devices equipped with movement sensors (such as an accelerometer) able to monitor movement over the using period, converting this information in data related to the sleep-wakefulness cycle. in this category, the reference devices are the actimeters/actigraphs (act). its use is recommended by the american academy of sleep medicine to the diagnosis of insomnia and circadian sleep disorders, and should be used for 3 to 14 consecutive days. other wearable devices, such as smartwatches, are also used with the same purpose, although not validated for clinical use. * wearable eeg band: eeg is a mandatory feature for type-1 polysomnography and a requirement for regular sleep staging. the project will utilize a wearable eeg band in combination with actigraphy and a ring oximeter to improve the estimation of sleep stages. this study will test wearable eeg bands with the following minimal specifications: dry eeg electrodes (no need for paste, gel, or other conductors), presented as a headband or stripe, a minimal sampling rate of 500hz, noise, high and low filters, a battery lasting at least 8 hours, a maximum weight of 200g (including the whole device), and support for bluetooth connection. * ring oximeter: the project will utilize a ring oximter to record the overnight blood oxygen levels, heart rates, and body movements.

Eligibility criteria:
inclusion criteria: * all genders * 3 to 18 years olnde * resident in the city of são paulo * candidate to perfome a polysomnography test at the sleep laboratory of the children's institute of the hospital das clínicas of the university of são paulo. exclusion criteria: * individuals with sleep efficiency lower than 85% on the night in question.
corona mortis in patients undergoing tep for inguinal hernia

Conditions: Inguinal Hernia; Pelvic Fracture; Acetabular Fracture; Bleeding

Summary: this study aim to describe the presence, type and size of corona mortis (cmor) in patients undergoing total extraperitoneal (tep) inguinal hernia repair procedures. this study also aim to describe the preperitoneal vascular anatomy of inguinal area and provide in vivo knowledge about cmor.

corona mortis is classically defined as the arterial and/or venous vascular anastomosis between the obturator artery and external iliac artery (most commonly the inferior epigastric artery) that crosses the posterior aspect of the superior ramus of the symphysis pubis. it runs along the posterior aspect of the superior pubic ramus and its laceration can prove life threatening in trauma cases or in scheduled operations. cmor is clinically important due to the potential risk of bleeding in pelvic fractures, pelvic and acetabular operations, surgery for urinary incontinence, oncologycal pelvic dissections and laparoscopic hernia repair. it requires special interests from different surgical branches, such as orthopedics, oncologic surgery, urogynecology and general surgery. vascular anatomy of retropubic area, especially cmor, should be kept in mind by surgeons performing laparoscopic surgery for hernia repair. in literature, the anatomical data have usually been come from studies performed on cadavers. the aim of this study was to provide in vivo knowledge about the presence, type (venous and/or arterial) and size of cmor in patients who underwent tep repair. 300 patients will undergo tep procedure for unilateral or bilateral inguinal hernias. tep procedures will be performed with three ports and one or three skin incisions. the presence and type of cmor will be evaluated, and picture will be made. the size of the cmor will be defined with ruler inserted true the 10 mm port.

Eligibility criteria:
inclusion criteria: * diagnosed primary or recurrence unilateral or bilateral inguinal hernia * age between 18 and 90; exclusion criteria: * patients who prefer other surgical approach than tep

Keywords: corona mortis tep inguinal hernia laparoscopic surgery anatomy inguinal region anatomy bleeding